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p53 is regulated by multiple posttranslational
modifications, including Hdm2-mediated ubiq-
uitylation that drives its proteasomal degrada-
tion. Here, we identify the p53-associated fac-
tor E4F1, a ubiquitously expressed zinc-finger
protein first identified as a cellular target of the
viral oncoprotein E1A, as an atypical ubiquitin
E3 ligase for p53 that modulates its effector
functions without promoting proteolysis. E4F1
stimulates oligo-ubiquitylation in the hinge re-
gion of p53 on lysine residues distinct from
those targeted by Hdm2 and previously de-
scribed to be acetylated by the acetyltransfer-
ase PCAF. E4F1 and PCAF mediate mutually
exclusive posttranslational modifications of
p53. E4F1-dependent Ub-p53 conjugates are
associated with chromatin, and their stimula-
tion coincides with the induction of a p53-
dependent transcriptional program specifically
involved in cell cycle arrest, and not apoptosis.
Collectively, our data reveal that E4F1 is a key
posttranslational regulator of p53, which modu-
lates its effector functions involved in alterna-
tive cell fates: growth arrest or apoptosis.
INTRODUCTION
p53 is a key regulator of cell cycle control, apoptosis, and
genomic stability in response to stress (Harris and Levine,
2005), and inactivation of the p53 pathway is a common
feature of cancer cells (Vogelstein et al., 2000). Genomic
insults lead to posttranslational modifications of p53 that
enhance its transcriptional activity and stability (BrooksCand Gu, 2003). Under normal growth conditions, interac-
tions between p53 and several ubiquitin (Ub) E3 ligases
(Alarcon-Vargas and Ronai, 2002; Brooks and Gu, 2006),
such as Hdm2/Mdm2 (Haupt et al., 1997; Kubbutat et al.,
1997), E6-AP (Scheffner et al., 1993), Cop1 (Dornan
et al., 2004), Pirh2 (Leng et al., 2003), and Mule/ARF-BP1
(Chen et al., 2005), maintain low levels of the p53 protein
by promoting its polyubiquitylation and degradation by
the 26S proteasome-dependent pathway (Michael and
Oren, 2003). The redundancy of these distinct E3 ligases
toward p53 regulation, and the physiological settings that
get them under way in vivo, remain largely unclear. Further-
more, some of the ubiquitylated lysines of p53 are subject
to competitive mono- and polyubiquitylation (Li et al.,
2003) and to several other modifications, including acety-
lation (Appella and Anderson, 2001; Ito et al., 2001; Kobet
et al., 2000), methylation (Chuikov et al., 2004), neddylation
(Xirodimas et al., 2004), and sumoylation (Bode and Dong,
2004; Gostissa et al., 1999; Melchior and Hengst, 2002;
Rodriguez et al., 1999; Schmidt and Muller, 2002). Notably,
competition between acetylation and ubiquitylation has
been documented at several lysines in the C terminus of
p53. While acetylation of human p53 on K372, K373,
K381, and K382 by the acetyltransferase CBP/p300 coin-
cides with p53 transcriptional activity, ubiquitylation of
some of these residues by Hdm2 targets p53 for degrada-
tion (Ito et al., 2002; Cheng et al., 2003; Liu et al., 1999; Luo
et al., 2001, 2000; Sakaguchi et al., 1998; Vaziri et al.,
2001). p53 is also acetylated in position K320 by the
CBP/p300-associated factor (PCAF) (Gu and Roeder,
1997; Liu et al., 1999; Sakaguchi et al., 1998), a modifica-
tion which has been proposed to direct p53 transcriptional
response toward growth arrest or apoptosis (Sakaguchi
et al., 1998; Terui et al., 2003, Knights et al., 2006).
Here, we report that E4F1 is an important modulator of
this K320 ubiquitylation/acetylation-dependent p53 re-
sponse. E4F1 is a ubiquitously expressed 120 kDa zinc-
finger protein of the GLI/Kruppel family that was firstell 127, 775–788, November 17, 2006 ª2006 Elsevier Inc. 775
identified as a cellular target of the viral oncoprotein
E1A13S, required for both transcriptional activation and
repression of adenoviral genes (Fernandes and Rooney,
1997; Lee and Green, 1987; Lee et al., 1987; Raychaudhuri
et al., 1987). Several recent observations suggest that
E4F1 also plays important roles during normal cell prolifer-
ation and survival. E4F1/ mouse embryos die at the
peri-implantation stage and exhibit mitotic progression
defects, chromosomal missegregation, and increased ap-
optosis (Le Cam et al., 2004). Conversely, ectopic expres-
sion of E4F1 in various cell lines results in inhibition of the
G1-S-phase progression and cytokinesis defects that cor-
relate with increased levels of the cell cycle inhibitor
p21Cip1 and the transcriptional repression of the cyclin
A2 gene (Fajas et al., 2000, 2001; Fernandes et al.,
1998, Rooney, 2001, Tessari et al., 2003). Notably, this
E4F1-mediated cell cycle arrest is reduced in cells defi-
cient for either pRB or p53 (Fajas et al., 2000; Sandy
et al., 2000), and is enhanced in the presence of p14ARF
(Rizos et al., 2003) and RASSF1A (Ahmed-Choudhury
et al., 2005), suggesting that E4F1 is involved in several
essential oncogenic pathways. Importantly, E4F1 physi-
cally interacts with these four tumor suppressors:
RASSF1A (Fenton et al., 2004), pRB (Fajas et al., 2000),
p14ARF (Rizos et al., 2003), and p53 (Sandy et al., 2000),
as well as with other regulators/effectors of these path-
ways: the proto-oncogene Bmi1 (Chagraoui et al., 2006),
the histone deacetylase HDAC1 (Colombo et al., 2003),
and FHL2 (Paul et al., 2006).
Here we present evidence that E4F1 is also an atypical
p53 Ub E3 ligase that regulates p53 effector functions.
E4F1-mediated ubiquitylation of p53 occurs at sites dis-
tinct from those targeted by Hdm2, competes with
PCAF-induced acetylation of p53, and does not target
p53 for proteasomal degradation. It is noteworthy that
these E4F1-stimulated p53-Ub forms are detectable on
chromatin and that their stimulation coincides with the re-
cruitment of p53 on growth arrest, but not on proap-
optotic, target genes. Consistently, E4F1 directs the p53
response toward growth arrest at the expense of apopto-
sis, suggesting that E4F1 plays an important role in the
cellular life-or-death decision controlled by p53.
RESULTS
E4F1 Has an Intrinsic Ubiquitin E3 Ligase Activity
that Drives K48-type Ubiquitylation of p53
While investigating the mechanisms that control the stabil-
ity of E4F1, we noticed that recombinant E4F1 was ubiq-
uitylated in vitro (Figure 1A) and stimulated the formation
of polyubiquitin chains in presence of recombinant Ub,
E1, and E2, and without addition of any E3 ligase in the as-
say (Figure 3B and Figure S1E in the Supplemental Data).
This suggested that E4F1 possess an intrinsic Ub E3 li-
gase activity. We next tested whether this activity was di-
rected against its known interactors, including p53,
p14ARF, and pRb. Whereas we failed to detect such an ef-
fect on pRb and p14ARF (data not shown), E4F1 efficiently776 Cell 127, 775–788, November 17, 2006 ª2006 Elsevier Inc.stimulated p53 ubiquitylation in vitro with various sources
of E4F1, p53, and Ub proteins, including recombinant
E4F1 purified from bacterial extracts (Figure 1B) and in-
sect cell lysates (Figures S1B–S1E), IVT E4F1 (Figure S1A),
and cellular E4F1 immunoprecipitated from U2OS cells
(Figure 1C). In vitro ubiquitylation assays with Ub mutants
bearing mutations on all but one of its lysines indicated
that lysine 48 was necessary for E4F1-stimulated oligo-
ubiquitylation of p53 (Figure 1D). All other Ub mutants sup-
ported only monoubiquitylation, suggesting that p53 was
ubiquitylated by E4F1 on a single lysine.
To investigate whether E4F1 could stimulate p53 ubiqui-
tylation in cells, we established a conditional E4F1 overex-
pression system based on the Cre-dependent activation of
a silent Lox-STOP-Lox E4F1-GFP expression vector (Fig-
ure S2D). This vector was stably integrated in U2OS, a cell
line with wild-type p53. Removal of the STOP element was
achieved by infecting cells with retroviral particles encod-
ing a ‘‘self-excising’’ CRE recombinase (Silver and Living-
ston, 2001) and resulted in the ectopic (10- to 12-fold
excess when compared with the endogenous E4F1), ho-
mogeneous, and stable expression of E4F1-GFP in the nu-
cleus of more than 85% of the cells (Figure 1E and Fig-
ure S2E). Ubiquitylation levels of endogenous (Figure 1F)
and ectopically expressed (Figure S2F) p53 were analyzed
in parental and LSL-E4F1 cells transfected with 6XHis-
tagged Ub construct. (Ni2+-NTA agarose)-purified Ub-
p53 conjugates were more abundant in cells expressing
E4F1-GFP than in control cells. Identical results were ob-
tained after transient transfection of U2OS cells with
E4F1 and p53 expression constructs (Figure S2C). Con-
versely, SiRNA-mediated depletion of endogenous E4F1
resulted in a major decrease of the basal ubiquitylation
levels of endogenous (Figure 1G) or ectopic (Figure S2B)
p53. Taken together, these data indicate that E4F1 is
a bona fide Ub E3 ligase for p53 in vitro and in vivo.
E4F1 Stimulates Ubiquitylation of p53 on Lysines
Distinct from Those Targeted by Hdm2
Stimulation of Ub chain polymerization by Hdm2 was pre-
viously shown to depend on six lysines in the C terminus of
human p53 (K370, K372, K373, K381, K382, and K386)
(Krummel et al., 2005; Li et al., 2003; Nakamura et al.,
2000; Rodriguez et al., 2000). It is noteworthy that a p53
mutant bearing K/R mutations of these six residues
(6KR) remained fully sensitive to E4F1-mediated ubiquity-
lation (Figures 2A and 2C and Figure S3A) while showing
greatly reduced ubiquitylation by Hdm2 (Figure 2B)
in vitro. A screen for p53 deletion mutants that block E4F1-
mediated ubiquitylation identified a region (aa 309–330)
within the ‘‘hinge region’’ of p53 (Figure S3B) that links
the DNA binding domain to the tetramerization domain
(Aurelio et al., 1998; Kong et al., 2001). This region con-
tains clustered lysines (K319, K320, and K321) whose
K/R mutation rendered p53 resistant to E4F1-mediated
ubiquitylation in vitro (Figure 2A) and in vivo (Figure 2C),
while preserving its sensitivity to Hdm2 (Figure 2B). These
data demonstrate that E4F1 stimulates the ubiquitylation
Figure 1. E4F1 Exhibits Intrinsic Ubiquitin E3 Ligase Activity on p53 In Vitro and In Vivo
(A) Autoubiquitylation activity of E4F1. Autoradiograms of in vitro ubiquitylation assays performed under standard conditions in presence of in vitro
translated (IVT) E4F1 labeled by 35S-methionine.
(B) Recombinant E4F1 stimulates p53 ubiquitylation in vitro. Autoradiograms of in vitro ubiquitylation assays performed with IVT 35S-labeled p53 and
GST-E4F1 or GST.
(C) Autoradiograms of in vitro ubiquitylation assays performed under standard conditions with IVT 35S-labeled p53 and cellular E4F1 immunoprecip-
itated from E4F1- or mock-transfected U2OS cells.
(D) E4F1 stimulates K48-Ub branching. Autoradiograms of in vitro ubiquitylation assays performed with IVT 35S-labeled p53, baculovirus expressed
E4F1 and Ub (WT), or Ub mutants bearing mutations of all (K0) or all but one of its lysine residues at the indicated position. Equal amounts of Ub mu-
tants were used in each assay (Figure S1F).
(E) Cre-induced E4F1-GFP expression in U2OS cells stably expressing the LSL-E4F1 construct. (Upper panels) Western blot analyses of nuclear
extracts prepared from LSL-E4F1 cells at the indicated time points after infection with Cre retrovirus, probed with anti-GFP, -E4F1, -p53 (DO1),
-Cre, and -TBP (loading control) antibodies (Abs). (Lower panels) Analysis of E4F1-GFP expression by fluorescence microscopy 3 days after infection
with Cre (+) or control () retroviruses. Cells are shown at 403 magnification.
(F) E4F1 stimulates ubiquitylation of endogenous p53 in vivo. Western blot analyses of Ub-conjugated proteins in LSL-E4F1 cells transiently trans-
fected for 24 hr with a 6XHis-Ub expression vector 4 days after infection by Cre (+) or control () retroviruses. One percent of cellular extracts were
probed for the presence of E4F1-GFP and total endogenous p53 using anti-GFP and anti-p53 (DO1) Abs (input). These cellular extracts, normalized to
contain equal amounts of total p53, were loaded on nickel (Ni+)-NTA columns. Ni+-purified 6XHis-Ub-conjugated proteins were probed for the pres-
ence of Ub-p53 forms using an anti-p53 (DO1) Ab (Ni-purified). Neither cells nor cellular extracts were treated with proteasome inhibitors.
(G) Depletion of endogenous E4F1 impacts on endogenous p53 ubiquitylation in vivo. Western blot analyses of Ub-conjugated proteins in U2OS cells
treated for 72 hr with control scramble or E4F1 SiRNAs. His-Ub-conjugated forms of endogenous p53 present in these cells were purified and an-
alyzed as described in Figure 1F.of p53 on the lysine cluster K319–K321, i.e., at sites dis-
tinct from those targeted by Hdm2. Consistent with the
notion that E4F1 ubiquitylates p53 independently of
Hdm2, this ubiquitylation was still detected in U2OS cells
treated with a Hdm2 SiRNA (Figure 2D).
Ubiquitin E3 Ligase Activity of E4F1 Requires
a Region with Similarities to the SUMO E3 Ligase
Domain of RanBP2
E4F1 contains a number of zinc finger motifs, including 9
C2H2 or C2HC Kru¨ppel-like zinc fingers likely involved inCeDNA binding (Fernandes and Rooney, 1999). However,
none of these zinc finger domains or other structured do-
mains of E4F1 showed obvious sequence similarities or
structural homologies with functional domains of known
E3 ligases, i.e., RING, HECT, or U-Box domains (Pickart
and Eddins, 2004). Nevertheless, a region located at the
N terminus of E4F1 (aa 30–80) presented similarities
(Figure 3A) with two regions (IR1 and IR2) that compose
the catalytic core domain of the SUMO E3 ligase RanBP2
(Pichler et al., 2004; Tatham et al., 2005). E4F1 bearing
a deletion within this region (D41–85E4F1) failed toll 127, 775–788, November 17, 2006 ª2006 Elsevier Inc. 777
Figure 2. E4F1 Stimulates p53 Ubiquitylation on LysineMotif K (319–321) In Vitro and In Vivo, at Sites Distinct from Those Targeted
by Hdm2
(A) In vitro ubiquitylation assays performed in presence of purified baculovirus-expressed E4F1 (+) or purified mock extract (), and with either IVT
35S-labeled WT or the 6KR or K(319–321)R mutant p53 proteins.
(B) In vitro ubiquitylation assays performed as in (A) but with GST-Hdm2 (+) or control GST () instead of E4F1.
(C) E4F1 stimulates p53 ubiquitylation at K319–K321) in vivo. Western blot analysis of Ub-conjugated proteins in Cre-infected (+) or mock-treated ()
LSL-E4F1 cells transiently cotransfected with 6XHis-Ub and either WT-p53, 6KR-p53, or K(319–321)R-p53 expression vectors. His-Ub-conjugated
forms of p53 were purified and analyzed as described in Figure 1F.
(D) Depletion of Hdm2 does not impact on the E4F1-stimulated ubiquitylation of p53 in vivo. Western blot analysis of Ub-conjugated proteins in Cre-
transduced parental (U2OS) and LSL-E4F1 cells transfected with p53 and His-Ub expression vectors, and treated for 48 hr with either control () or
Hdm2 SiRNAs (+). His-Ub-conjugated forms of p53 were purified and analyzed as described in Figure 1F.promote polyubiquitin chain formation (Figure 3B) and p53
ubiquitylation in vitro and in vivo (Figures 3C and 3D).
Importantly, both WT and D41–85E4F1 proteins were
expressed at comparable levels in the nucleus (Figures
3D and 4B) and exhibited similar capacities to interact
with p53 (Figure S4B).
Considering that E4F1 contains an atypical E3 domain,
we also tested whether p120E4F1 recombinant protein
(full-length E4F1) could also function as a SUMO or
Nedd8 E3 ligase for p53, but failed to detect such activity
in experimental conditions where the SUMO 1-conjugat-
ing E3 PIAS1 and Hdm2 enhanced p53 sumoylation and
neddylation, respectively (Figure 3E).
E4F1-Mediated Ubiquitylation Results Neither
in Destabilization nor Relocalization of p53
Ubiquitylation of p53 has been previously associated with
its proteasomal degradation and cytoplasmic/nuclear
shuttling (Haupt et al., 1997; Kubbutat et al., 1997; Li778 Cell 127, 775–788, November 17, 2006 ª2006 Elsevier Inc.et al., 2003). Surprisingly, E4F1-stimulated p53-Ub conju-
gates were easily detectable in absence of proteasome
inhibitors, suggesting that E4F1 does not stimulate
proteasome-dependent p53 degradation. Consistently,
E4F1-GFP induction did not result in decreased levels of
endogenous or ectopically expressed p53 (Figures 4A,
4B, and data not shown). On the contrary, evaluation of
p53 protein decay in LSL-E4F1 cells treated with cyclo-
heximide showed that E4F1 expression induced a moder-
ate, but reproducible, stabilization of endogenous p53
(Figure 4A). Moreover, biochemical fractionation and
immunofluorescence analysis indicated that cellular
localization of endogenous p53 changed neither upon
E4F1-GFP induction (Figure 4B and Figure S4A) nor
upon depletion of endogenous E4F1 (Figure 4C).
Thus, in striking contrast to the ubiquitylation mediated
by hitherto described p53 E3 ligases, E4F1-mediated
ubiquitylation results in neither protein degradation nor
changes in the cytoplasmic/nuclear shuttling of p53.
Figure 3. TheUbiquitin E3 Ligase Activity
of E4F1 Requires a Region Showing Se-
quence Similarities with the IR1 and IR2
Regions of the SUMO E3 Ligase Domain
of RanBP2
(A) Sequence alignments of the IR1 and IR2 do-
mains from RanBP2 with the N-terminal region
of E4F1 (aa 32–81). Residues whose mutation
has been shown to affect RanBP2 E3 ligase ac-
tivity are marked with a check.
(B) The aa 41–85 region of E4F1 is required for
polyubiquitin chain formation in vitro. Western
blot analysis of in vitro ubiquitylation assays
performed in presence of similar amounts of
baculovirus-expressed WT full-length E4F1
(p120E4F1), D41–85E4F1 proteins, or mock-
purified preparations (). Poly-Ub chains are
revealed with an anti-Ub Ab (upper panel).
Immunoblotting with anti-E4F1 (AD1) Abs
show that equal amounts of WT and D41–85
E4F1 proteins have been added in each assay
(lower panel).
(C) E4F1-mediated ubiquitylation of p53 in vitro
requires the aa 41–85 region of E4F1. Autora-
diograms of in vitro ubiquitylation assays per-
formed with 35S-labeled IVT p53 and increasing
amounts of baculovirus-expressed WT E4F1
(p120E4F1) or D41–85E4F1 proteins (upper
panel). Immunoblotting with anti-E4F1 (AD1)
Ab showing the amounts of WT and D41–85
E4F1 proteins added in each assay (lower
panel).
(D) E4F1-mediated ubiquitylation of p53 in vivo
requires aa 41–85 region of E4F1. Western blot
analysis of Ub-conjugated proteins in Cre-
transduced (+) or mock-treated (), parental,
LSL-E4F1 and LSLD41–85E4F1 cells, trans-
fected with 6XHis-Ub and p53 expression
vectors. His-Ub-conjugated forms of p53
(ectopic + endogenous) were purified and ana-
lyzed as described in Figure 1F.
(E) Full-length p120E4F1 does not exhibit SUMO or Nedd8 E3 ligase activity in vitro. Recombinant p120E4F1, Hdm2, or PIAS1 proteins were incubated
under standard ubiquitylation (left panel), sumoylation (middle panel), or neddylation (right panel) conditions in presence of baculovirus-expressed
p53 protein. p53 conjugates were analyzed by western blotting with anti-p53 antibody (DO1).p53 forms Ubiquitylated by E4F1 Are Localized
on Chromatin
Another difference between p53 forms ubiquitylated by
E4F1 or Hdm2 was revealed by assessing their associa-
tion with chromatin using a small-scale chromatin frac-
tionation assay (Wysocka et al., 2001). This assay was ap-
plied to cell lysates from U2OS cells expressing p53 and
E4F1 or Hdm2, and showed that E4F1-stimulated Ub-
p53 forms were predominantly found in chromatin-en-
riched fractions (P3), whereas Hdm2-stimulated Ub-p53
forms mainly localized in soluble fractions (S) (Figure 4D).
Similar results were observed in LSL-E4F1 cells, but not
in LSLD41–85E4F1 cells, with endogenous Ub-p53 forms
stimulated by E4F1 (Figure 4E). Importantly, these Ub-p53
forms present in P3 were solubilized by brief Micrococcal
Nuclease (Mnase) treatment (Figure 4F), as was HCF1,
a chromatin-associated protein monitored in parallel (Wy-Csocka et al., 2001). These data indicate that the E4F1-
stimulated Ub-p53 forms were associated with chromatin,
and not associated in other insoluble structures. Although
indirectly so, these observations suggest that E4F1-stim-
ulated Ub-p53 forms could be transcriptionally active, and
further support the notion that E4F1 and Hdm2 control dis-
tinct p53 fates.
E4F1 Induces a p53-Dependent Growth Arrest
Gene expression profiling assays performed in LSL-E4F1
cells identified several p53 target genes involved in cell cy-
cle arrest whose expression was activated upon E4F1 ex-
pression, including p21Waf1, Gadd45a, and Cyclin G1
(E.J., L.L., and C.S., unpublished data). In contrast, those
experiments did not reveal variations of p53 targets in-
volved in apoptosis, such as Fas, Killer/DR5, Bax, Noxa,
or p53AIP1 (data not shown). RT-PCR analyses confirmedell 127, 775–788, November 17, 2006 ª2006 Elsevier Inc. 779
Figure 4. E4F1-Mediated Ubiquitylation of p53 Results in Neither p53 Destabilization nor Nuclear Export
(A) E4F1 overexpression results in a moderate stabilization of endogenous p53 protein. Half-life of p53 protein was measured in cycloheximide- (CHX)
treated parental or LSL-E4F1 5 days after Cre-transduction. Protein extracts, prepared at indicated time points after CHX addition, were analyzed by
western blotting with anti-E4F1, -p53 (DO1), and -tubulin Abs (upper three panels). (Lower panel) Quantification of the ratio of p53/tubulin (mean
values of two independent experiments).
(B) The nuclear/cytoplasmic distribution of p53 does not change upon ectopic E4F1 expression. Western blot analysis of nuclear and cytoplasmic
extracts prepared from Cre-infected parental, LSL-E4F1, and LSLD41–85E4F1 cells with anti-p53 (D01), -GFP, -TBP, or -tubulin Abs.
(C) The nuclear/cytoplasmic distribution of p53 does not change upon depletion of endogenous E4F1. Western blot analysis of nuclear and cytoplas-
mic extracts, prepared from U2OS cells treated for 72 hr with either control scrambled SiRNA (Scr) or E4F1 SiRNAs, and probed with anti-E4F1, -p53
(DO1), -TBP, or -Mek5 Abs.
(D) E4F1-, but not Hdm2-, stimulated Ub-p53 forms localize in chromatin-enriched fraction. U2OS cells were transiently cotransfected with 6XHis-Ub
and p53 together with either E4F1, Hdm2, or control expression vectors. Cell lysates were fractionated into fractions S2 (soluble cytosolic and some
soluble nuclear components), S3 (soluble nuclear components), and P3 (insoluble chromatin and nuclear matrix components). His-Ub-conjugated
forms of p53 (ectopic + endogenous) present in each fraction were purified and analyzed as described in Figure 1F. Cells transfected with Hdm2
were treated for 2 hr with the proteasome inhibitor MG132 prior to the biochemical fractionation.
(E) Endogenous Ub-p53 forms stimulated by E4F1 localize in the chromatin-enriched fraction. Western blot analysis of Ub-conjugated proteins pres-
ent in fractions P3, S2, and S3 prepared from parental U2OS, LSL-E4F1, or LSLD41–85E4F1 cells 5 days after Cre-transduction. His-Ub-conjugated
forms of endogenous p53 present in each fraction were purified and analyzed as described in Figure 1F. Mek5 was used to assess the quality of the
biochemical fractionation.
(F) Digestion of chromatin by Micrococcal Nuclease (Mnase) releases the E4F1-stimulated Ub-p53 forms from the chromatin-enriched fraction P3. P3
fractions prepared from LSL-E4F1 cells were treated with Mnase (+) or with mock enzymatic buffer (). Digested suspensions were centrifuged and
His-Ub-conjugated p53 forms were purified from both the supernatant (sup) and the pellet (P) as described in Figure 1F. Ni+-purified His-Ub-conju-
gated proteins (Ni-purified) and a fraction of corresponding input extracts were probed for the presence of p53 and HCF1 (a control protein tightly
associated with chromatin) by immunoblotting using anti-p53 (DO1) and -HCF1 Abs.these results (Figures 5A, 5B, and data not shown). Impor-
tantly, p21Waf1 and Cyclin G1 inductions were not de-
tected in LSLD41–85E4F1 cells (Figure 5A) or LSL-E4F1
cells stably expressing short hairpin RNAs (ShRNAs)
against p53 ((LSL-E4F1)Dp53; Figure 5B). These results
suggested that the E3 activity of E4F1 activates a subset
of the p53 transcriptional program. Consistently, chroma-
tin immunoprecipitation (ChIP) assays showed enhanced
recruitment of p53 on the p21, but not the NOXA, pro-
moter region, upon E4F1 ectopic expression (Figure 6E).
The induction of this p53 transcriptional program led to
the accumulation of E4F1-GFP-positive cells in the G1780 Cell 127, 775–788, November 17, 2006 ª2006 Elsevier Inc.phase of the cell cycle (Figure 5C), and the gradual loss
of E4F1-GFP expressing cells in the total cell population
(Figure 5D). Importantly, Annexin-V staining of LSL-E4F1
cells indicated that the E4F1-induced growth defect was
not the consequence of enhanced cell death (Figure 6A).
Notably, this growth defect was partly rescued in cells
stably expressing ShRNAs directed against p53 and
p21WAF1(Figures 5C and 5D), confirming the role of the
p53 pathway in this process. A similar growth defect
was not observed in LSLD41–85E4F1 cells, indicating
that it depends on the E3 activity of E4F1. Moreover, while
cooperation to induce cell cycle arrest was obtained
Figure 5. E4F1 Induces a p53-Dependent Growth Arrest Transcriptional Program that Requires Its E3 Ligase Activity
(A) E4F1, but not the E3 ligase mutant D41–85E4F1, stimulates expression of a subset of p53 target genes. Quantitative RT-PCR (QRT-PCR) analysis
of p21Waf1, cyclin G1, and NOXA gene expression in parental, LSL-E4F1, and LSLD41–85E4F1 cells at indicated time points following Cre- transduc-
tion. The data show the mean values obtained by QRT-PCR in three independent experiments.
(B) E4F1-mediated activation of p21Waf1 and cyclin G1 genes is p53-dependent. Semiquantitative RT-PCR analysis of p21 and cyclin G1 mRNAs in
Cre-transduced LSL-E4F1 cells stably expressing either a control ShRNA (CTL) or a ShRNA designed to knock down human p53 (ShRNA p53).
(C) E4F1-GFP expression results in a p53-dependent and E3 ligase-dependent growth arrest with cells accumulating in G0/G1. LSL-E4F1, LSLD41–
85E4F1, and LSL-E4F1 stably expressing p53 ShRNA were harvested at the indicated time points after Cre-infection, and DNA content was analyzed
by propidium iodide (PI) staining/FACSscan analysis. PI profiles of E4F1-GFP-positive (+) and -negative () cells from the same cell population were
analyzed. Data represents the mean ± SD of three independent experiments.
(D) E4F1-mediated growth defects are p53-dependent and require its Ub E3 ligase activity. Percentage of GFP-positive cells present in each cell
population at the indicated time points after Cre-treatment of LSL-E4F1-GFP (E4F1) or LSLD41–85E4F1-GFP (D41–85) cells. Similar experiments
were performed on LSL-E4F1-GFP cells stably expressing ShRNAs directed against p53 (E4F1/Dp53), p21Waf1 (E4F1/Dp21), or control genes.
Data represent the mean of three independent experiments.
(E) Lysine 320 of p53 is involved in E4F1-mediated cell cycle arrest. U2OS cells were transduced with control, WT p53, or K320R mutant p53 retro-
viruses (harboring also a CMV-GFP cassette) and transiently transfected for 24 hr with E4F1, D41–85E4F1, or empty control expression constructs.
Cells were then incubated for 20 hr with BrdU, and both GFP-positive and E4F1-positive cells were assessed for BrdU uptake by immunofluores-
cence. Histograms represent the percentage of BrdU positive cells relative to control cells (control retrovirus + empty expression construct) set at
100 in arbitrary units. Statistical analyses were performed using ANOVA and Student-Newman-Keuls multiple comparisons tests. Data represents
the mean ± SD of three independent experiments. NS, not significant.in cells transiently overexpressing E4F1 and p53, this was
observed neither with the DE3-E4F1 mutant nor with p53
mutated on its E4F1-ubiquitylation site (K320R-p53)
(Figure 5E).
Altogether, these data suggest that E4F1-mediated
ubiquitylation of p53 on K320 promotes the transcriptional
activation of a subset of p53 target genes involved in cell
cycle arrest.
E4F1 Exhibits p53-Dependent Antiapoptotic
Activities
We next investigated whether E4F1 could also modulate
the cellular response to p53-dependent apoptotic stimuli,
such as UVC irradiation or p14ARF overexpression.Annexin-V staining of UVC-irradiated LSL-E4F1 and
LSLD41–85E4F1 cells revealed that cells overexpressing
WT E4F1 were less prone to undergo UVC-induced apo-
ptosis than parental cells or cells expressing the E3 dele-
tion mutant (Figure 6A). Conversely, treatment of U2OS
cells with E4F1 SiRNAs resulted in increased spontaneous
cell death as well as potentiation of UVC- and p14ARF-
induced apoptosis (Figures 6B and 6C, respectively). Al-
though incompletely so, this cell death induced by E4F1
depletion was rescued in cells stably expressing ShRNA
directed against p53 (Figures 6B and 6C).
Consistent with the notion that E4F1 interferes with
proapoptotic functions of p53, we also observed that
E4F1 overexpression decreased the UVC-dependentCell 127, 775–788, November 17, 2006 ª2006 Elsevier Inc. 781
Figure 6. E4F1 Exhibits p53-Dependent
Antiapoptotic Activities
(A) E4F1 ectopic expression protects cells from
UVC-induced cell death. Five days after Cre-in-
fection, LSL-E4F1 and LSLD41–85E4F1 cells
were exposed to UVC (15 J/m2) and analyzed,
36 hr later, for Annexin-V staining by FACSs-
can. Infection conditions were set to ensure
that 50% of the cells express the E4F1-GFP
transgene. Histograms represent the percent-
age of Annexin-V-labeled cells among GFP-
positive and -negative cells from the same
dish. Data are the mean ± SD of six indepen-
dent experiments.
(B) E4F1 depletion sensitizes U2OS cells to
UVC-induced cell death. This effect is only
partly p53-dependent. U2OS cells stably ex-
pressing either control-ShRNAs (Sh Ctr) or
p53-ShRNAs (Sh p53) were transiently trans-
fected for 3 days with control scrambled SiRNA
(Scr, open box) or E4F1-SiRNA (E4F1, black
box). Cells were then exposed to UVC (15 J/
m2) and analyzed, 24 hr later, for Annexin-V
staining by FACSscan. The data represent the
mean ± SD of three independent experiments.
Statistical analysis was performed using
a paired t test. E4F1 and p53 depletions were
assessed by immunoblotting (upper panels).
(C) E4F1 depletion sensitizes U2OS cells to cell
death induced by overexpression of p14ARF.
Annexin-V-positive cells were determined by
FACSscan after treatment of U2OS cells with
either control SiRNA (Scr, open box) or E4F1-
SiRNA (black box) and transduction with either
empty () or p14ARF (+) retroviruses. These ex-
periments were performed in parallel in U2OS
cells stably expressing p53 (Shp53) or control
(Sh Ctr) ShRNAs. Data are the mean ± SD of
three independent experiments. Statistical
analysis was performed using a paired t test.
(D) E4F1 ectopic expression decreases the
UVC-induced activation of the proapoptotic
gene NOXA. Five days after Cre-transduction, parental and LSL-E4F1 cells were mock-treated or UVC-irradiated (15 J/m2). Six hours after irradiation,
NOXA mRNA expression was assessed by QRT-PCR. Data shown are the mean values ± SD of two independent experiments.
(E) Chromatin immunoprecipitations assays (ChIP) showing that E4F1 stimulates the recruitment of endogenous p53 at the p21 promoter, but not at
the NOXA promoter, region. Five days after Cre-transduction, parental and LSL-E4F1 cells were mock-treated or UVC-irradiated (15 J/m2). Six hours
later, similar amounts of formaldehyde-cross-linked chromatin samples were immunoprecipitated with anti-p53 (DO7) or control Ig, and precipitates
were analyzed by quantitative PCR for the presence of human p21Waf1 and NOXA promoter fragments (centered around the major p53 sites). Histo-
grams represent the ratio between the fraction of input promoter DNA (p21 or NOXA) immunoprecipitated by the anti-p53 antibody and DNA immu-
noprecipitated by the control Ig. Histograms represent the mean values ± SD of three independent experiments.induction of the proapoptotic p53 target gene NOXA
(Q-RT-PCR, upper panel, Figure 6D) and the coincidental
recruitment of p53 on the NOXA promoter region (Fig-
ure 6E). In these UV-irradiated E4F1-overexpressing cells,
p53 recruitment on the p21 promoter remained high
(Figure 6E), a situation which coincided with the mainte-
nance of a high level of p53 ubiquitylation (Figure S6C).
Taken together, these data strongly argue that E4F1-
mediated ubiquitylation causes p53 to trigger activation
of a transcriptional program involved in cell cycle arrest
and antagonizes p53 ability to induce apoptosis.782 Cell 127, 775–788, November 17, 2006 ª2006 Elsevier Inc.E4F1-Stimulated Ubiquitylation Antagonizes p53
Acetylation by PCAF
The lysines of p53 targeted by E4F1 include K320, a resi-
due previously shown to be acetylated by the acetyltrans-
ferase PCAF in response to various cellular stressors
leading to apoptosis (Liu et al., 1999), as shown here in
U2OS irradiated by UVC (Figures 7A and 7B and
Figure S6B). We hypothesized that PCAF and E4F1 medi-
ate competitive posttranslational modifications of p53 on
K320. Such competition between acetylation and ubiqui-
tylation has previously been reported on other p53 lysines
Figure 7. E4F1-Mediated Ubiquitylation
of p53 Antagonizes the UVC-Stimulated
and PCAF-Mediated Acetylation of K320
(A) Acetylation of K320 inversely correlates with
ubiquitylation of p53 in UV-irradiated U2OS
cells. U2OS cells were UVC-irradiated (15 J/
m2) (+) or mock treated (). Four hours later,
endogenous p53 was immunoprecipitated
(DO7) and precipitates were probed by immu-
noblotting with an antibody recognizing either
the K320-acetylated form of p53 (upper left
panel) or all forms of p53 (FL393) (lower left
panel). In parallel, ubiquitylation levels of en-
dogenous p53 were assessed as described in
Figure 1F (right panels). Neither cells nor cellu-
lar extracts were treated with proteasome
inhibitors.
(B) E4F1 ectopic expression decreases UVC-
induced acetylation of endogenous p53 on
K320. Four hours after UVC irradiation (15 J/
m2) (+) or mock-treatment () of parental
U2OS, LSL-E4F1, and LSLD41–85E4F1 cells,
the PCAF-mediated acetylation on K320 and
CBP/p300-mediated acetylation on K373 of
endogenous p53 were assessed by IP-western
experiments as described in Figure 7A. Immu-
noblottings were performed with antibodies
recognizing either the K320- or K373-acety-
lated forms of p53.
(C) E4F1 depletion enhances UVC-induced
acetylation of p53 on K320. Four hours after
UVC irradiation, acetylation levels of K320
and K373 of endogenous p53 were assessed,
as in Figure 7B, in U2OS cells treated for three
days with control scrambled (scr) or E4F1
SiRNAs.
(D) E4F1-mediated ubiquitylation of recombi-
nant p53 directly competes for PCAF-induced
acetylation on residue K320 of p53 in vitro.
Combinations of recombinant PCAF, p53, and
WT or D41–85 E4F1 proteins were incubated with acetylation mix under standard conditions and then immunoblotted with Abs recognizing either
the K320-acetylated form of p53 (upper panels) or all forms of p53 (DO1) (lower panels). E4F1-mediated ubiquitylation reactions were performed
as described in Figure 1 prior to the acetylation reaction. CUbm, ubiquitylation mix: E1, E2, Ub, ATP.
(E) E4F1 expression protects cells from the sensitizing effects of PCAF to UVC-induced cell death. LSL-E4F1 cells were transiently transfected with
empty () or PCAF expression vectors and exposed to UVC (15 J/m2). Six hours after irradiation, E4F1-GFP-positive and GFP-negative cells were
analyzed for Annexin-V staining by FACSscan. Data are the mean ± SD of two independent experiments.
(F) Schematic representation of posttranslational modifications occurring at p53 lysine clusters K319–K321 and K370/372/373/381/382/386. Both
clusters are subjected to mutually exclusive posttranslational modifications performed by acetyl-transferases (PCAF and CBP/p300, respectively)
and Ub E3 ligases (E4F1 and Hdm2, respectively). Based on our results, we propose that these modifications have different output signals for
p53 effector functions. Competition between PCAF-mediated acetylation and E4F1-mediated ubiquitylation at K320 modulates p53 ability to induce
either growth arrest or apoptosis.(including K373) that are targeted by p300/CBP and
Hdm2.
Consistent with this model, the UVC-stimulated acety-
lation of K320 (Figure 7A) coincided with a decrease in
the basal level of p53 ubiquitylation (mainly ascribable
to E4F1 activity in those experimental conditions as
shown in Figure 1F). Conversely, p53 acetylation on
K320, but not on K373, was compromised in cells
overexpressing E4F1 (Figure 7B) and potentiated upon
SiRNA-mediated depletion of endogenous E4F1C(Figure 7C). Finally, in vitro K320 acetylation of recombi-
nant p53 by recombinant PCAF was abolished when
p53 was first ubiquitylated in vitro by E4F1 (Figure 7D).
In contrast, in vitro acetylation of K373 mediated by
p300 remained unaffected by E4F1 (Figure S5A). Impor-
tantly, E4F1 did not perturb acetylation of purified His-
tone H3, another PCAF substrate (Figure S5B), indicating
that the decreased acetylation of p53 on K320 was not
the indirect consequence of an alteration of PCAF acetyl-
transferase activity.ell 127, 775–788, November 17, 2006 ª2006 Elsevier Inc. 783
Of note, the in vivo competition between ubiquitylation
and acetylation on K320 was not observed upon ionizing
irradiation of U2OS cells (Figures S6B and S6C), an exper-
imental condition which induces DNA double-strand
breaks and p53 activation without inducing cell death in
this cell line (Allan and Fried, 1999).
Collectively, these data indicate that E4F1 and PCAF
mediate mutually exclusive posttranslational modifica-
tions of p53, a mechanism that might explain the control
of E4F1 over p53-dependent induction of cell death
(Figure 7E).
DISCUSSION
E4F1 was originally identified as an E1A-activated cellular
transcription factor that directly associates with several
important cellular regulators, including p53. Here, we
show that E4F1 is also a bona fide Ub E3 ligase for p53,
although it contains none of the typical domains previ-
ously described in other Ub E3 ligases. Instead, a region
of E4F1 (aa 30–80) required for its Ub E3 activity presents
sequence similarities with IR domains of the SUMO E3 li-
gase RanBP2. Despite these similarities, full-length E4F1
was unable to promote in vitro conjugation of SUMO 1
or, like Hdm2, of Nedd8 on p53. At this stage, we can
not formally rule out the possibility that E4F1 can also
function as a SUMO E3 in vivo under specific conditions
or toward other substrates. However, it is tempting to
speculate that E4F1 and RanBP2 E3 domains originate
from a common ancestor, but have evolved to favor Ub
or SUMO conjugation, a situation already observed with
RING-type E3 domains.
E4F1-mediated oligo-ubiquitylation occurs in the lysine
cluster K319–K321 of p53. These acceptor lysines are dis-
tinct from those targeted by Hdm2, and consistently, their
ubiquitylation is Hdm2-independent. In striking contrast
with previously described p53-Ub E3, we found that
E4F1 overexpression neither changes the p53 nuclear/cy-
toplasmic ratio nor destabilizes p53. Accordingly, these
E4F1-mediated p53-Ub conjugates were readily observed
in cellular extracts without addition of proteasome inhibi-
tors, reinforcing the notion that this modification does
not target p53 to degradation. This was unexpected, since
E4F1 predominantly favors Ub chain extension via K48,
a branching type generally associated with proteasomal
degradation. Nevertheless, there is evidence that the abil-
ity of K48 polyubiquitylated proteins to physically interact
with the 26S proteasome relies on the length of the Ub
chain (Thrower et al., 2000). Of note, E4F1-modified p53
Ub-conjugated ladders generated in our assays are
shorter than those observed with Hdm2 (Figure 3E).
In striking contrast with Ub-p53 forms stimulated by
Hdm2, which are mainly cytosoluble and targeted to the
proteasome, we found that E4F1-stimulated Ub-p53
forms are tightly associated with chromatin, suggesting
that they could be involved in transcription. Consistent
with this notion, stimulation of the E4F1-mediated ubiqui-
tylation of p53 coincides with the selective activation of784 Cell 127, 775–788, November 17, 2006 ª2006 Elsevier Inc.p53 responsive genes involved in growth arrest, including
p21 and cyclin G1, but not of those involved in apoptosis.
Accordingly, ChIP assays indicate that E4F1 stimulates
the recruitment of p53 on the p21 promoter, but not on
its proapoptotic target-gene, NOXA. Interestingly, similar
scenarios were recently reported about the ubiquitylation
of the transcription factors Met4 and c-Myc, which pro-
motes their recruitment to some, but not all, of their target
genes (Adhikary et al., 2005; Flick et al., 2004).
Importantly, this E4F1-mediated activation of p53 is un-
likely to be an indirect consequence of E4F1-induced DNA
damage, since E4F1-overexpressing cells do not exhibit
specific phospho-Ser139 g-H2AX staining (Figure S6D)
or enhanced phosphorylation of p53 on Ser15 (Fig-
ure S6E).
In addition, our data suggest that E4F1 exhibits antia-
poptotic properties that depend on its E3 activity and, at
least in part, on p53. This activity unlikely results from al-
terations of upstream signaling pathways that activate
p53 in response to UVC-irradiation, since phosphorylation
of p53 on Ser15 occurred at similar levels in control and
E4F1-overexpressing cells after UVC irradiation (Fig-
ure S6E). Endogenous E4F1 seems to exert a similar cyto-
protective function, since SiRNA-mediated depletion of
E4F1 in U2OS cells resulted in spontaneous cell death
and in increased apoptosis in response to UVC and
p14ARF overexpression. However, p53 depletion incom-
pletely rescues this cell death induced by E4F1 depletion,
suggesting that the impact of E4F1 on survival extends
beyond its effects on p53. Of note, gene expression pro-
filing of LSL-E4F1 cells also identified several p53-inde-
pendent survival genes whose expression was activated
upon E4F1 expression, among which are members of
the BCL and IGF families (E.J., L.L., and C.S., unpublished
data).
How does E4F1-stimulated ubiquitylation modulate the
p53 transcriptional activity? Hypotheses similar to the
‘‘histone code’’ have been advanced for the panoply of
p53 posttranslational modifications, where multisite and
competing modifications are important for coordinating
qualitative and quantitative aspects of p53 functions
in vivo (Yang, 2005). Consistent with the model that differ-
ent modifications of p53 create gridlock at its C-terminal
lysine residues, with one modification excluding others
(Chuikov et al., 2004; Saito et al., 2003; Sakaguchi et al.,
1998), we found that E4F1-mediated ubiquitylation com-
petes for acetylation of K320 by PCAF, but leaves intact
its capacity to be acetylated by CBP/p300. In contrast to
the plethora of information regarding the regulation of
p53 by CBP/p300, the roles of PCAF in p53-dependent
stress-induced cell death/growth arrest remain unclear
and controversial (Sakaguchi et al., 1998, Di Stefano
et al., 2005, Knights et al., 2006). In U2OS cells, we found
that p53 is rapidly acetylated on K320 and K373 after UVC
irradiation at a dose that induces a strong apoptotic re-
sponse. In contrast, this K320 acetylation was barely de-
tectable upon exposure to ionizing radiation, which acti-
vates p53 but does not induce cell death in this cell line.
This might explain why E4F1-mediated ubiquitylation
does not perturb the G2 cell cycle arrest induced by dou-
ble-stranded DNA breaks (Figure S6F), a phenomenon
that correlates with acetylation of p53 by CBP (K373),
but not PCAF (K320). Moreover, we found that PCAF over-
expression sensitizes cells to UVC-induced apoptosis.
Collectively, these data strongly support a role for PCAF-
stimulated acetylation of p53 on K320 in apoptosis, at
least in U2OS cells. Consistent with this model, we pro-
pose that E4F1 antagonizes the PCAF-mediated acetyla-
tion of p53 and ability to trigger an apoptotic program in
response to UVC. This E4F1-p53-PCAF model also pro-
vides new directions for exploring the poorly understood
capacity of p53 to choose between a cell cycle arrest or
apoptotic transcriptional program (Oren, 2003; Vousden
and Lu, 2002). Based on this model, it could be interesting
to reanalyze naturally occurring p53 mutants that exhibit
different abilities to induce cell cycle arrest or apoptosis
(Friedlander et al., 1996; Rowan et al., 1996; Ryan and
Vousden, 1998) for their capacity to be either preferentially
acetylated by PCAF or ubiquitylated by E4F1. Notably,
p53 mutations/deletions near the lysine cluster 319–320
have already been shown to affect its capacity to induce
apoptosis, but not growth arrest (Kong et al., 2001).
While the competition between PCAF and E4F1 pro-
vides an explanation for how E4F1 antagonizes the ex-
pression of proapoptotic genes, it does not address the
molecular mechanism by which E4F1-stimulated K48
oligo-ubiquitylation promotes the activation of p53-
responsive genes involved in growth arrest. This might oc-
cur through the mild stabilization of p53 that is detected
in cells overexpressing E4F1. However, the degree of
this stabilization appears to be too moderate to explain
by itself the robust p53-dependent cell cycle arrest ob-
served in these cells. It seems more likely that multiple
mechanisms are involved in a way reminiscent of the acet-
ylation of p53 at K382 that enhances DNA binding (Gu and
Roeder, 1997; Luo et al., 2004), blocks ubiquitylation by
Hdm2 (Nakamura et al., 2000), and specifically interacts
with the bromodomain of CBP (Barlev et al., 2001; Espi-
nosa and Emerson, 2001; Prives and Manley, 2001). Thus,
it is possible that the K320 ubiquitylation of p53 also en-
hances physical interactions with transcriptional regula-
tors such as other transcription factors, coactivators, or
components of the basal transcriptional machinery.
In conclusion, our data show that E4F1 is a bona fide Ub
E3 ligase for the p53 tumor suppressor both in vitro and
in vivo. To our knowledge, this is the first example of
p53-Ub forms that are associated with chromatin and
are not linked to p53 inactivation. E4F1 plays a unique
role in the p53 pathway as a novel component of the mo-
lecular switch that directs p53 toward cell cycle arrest or
apoptosis. As such, it will be of considerable interest to
identify pathways/signals that trigger the physiological
activation of E4F1 Ub E3 activity, and to evaluate its impli-
cation in tumorigenesis. Interestingly, it was recently
unraveled that there exists a physical and functional link
between Bmi1 and E4F1 in hematopoietic stem cellsC(Chagraoui et al., 2006). Given the key role of Bmi1 in
the regulation of the ARF-p53 pathway, it will be of great
interest to address the role of Bmi1 on E4F1-mediated
ubiquitylation of p53 in vivo.
EXPERIMENTAL PROCEDURES
In Vivo Ubiquitylation Assay
5.106 U2OS cells were transfected using Fugene (Roche) with 5 mg of
6XHis-tagged Ub and 2.5 mg of p53 expression constructs. Cells were
lysed under denaturing conditions 24 hr after transfection. Briefly, cells
were resuspended in 10 ml of denaturing buffer (6 M guanidinium-HCl,
0.5% Triton, 10 mM imidazole, 20 mM Tris-HCl [pH 8], 0.5 mM DTT,
and 0.5 mM Iodoacetamide). His–Ub conjugated proteins were puri-
fied by nickel chromatography (Ni-NTA Agarose; Qiagen). Nickel-
bound ubiquitylated proteins were subjected to western blot analysis
using anti-p53 Ab (DO1). Note that levels of ubiquitylation were as-
sessed on an equal amount of p53 proteins, as shown by western blot-
ting of an unpurified fraction of the same extracts.
Generation of LSL-E4F1 Inducible Cell Lines
The WT full-length human E4F1 cDNA was cloned into pEGFP-N1
plasmid (Clontech). The D41–85 deletion of E4F1 was generated by
PCR using the following oligonucleotides (50 GCCTTGGCCCCCAG
CGCCCCTCCGGAGGCC30 and 50 GGCCTCCGGAGGGGCGCTGG
GGGCCAAGGC30 ). After introduction of a transcriptional STOP cas-
sette flanked by Lox-P sequences (Jackson et al., 2001), both con-
structs were stably transfected into U2OS cells. Puromycin-resistant
clones were checked for Cre-inducible expression of the E4F1-GFP
proteins by FACSscan analysis. Several independent clones express-
ing comparable levels of WT and D41–85 E4F1 protein were used.
Small-Scale Chromatin Fractionation Assay
4.107 U2OS cells transfected with a His-tagged Ub expression con-
struct were collected for preparation of subcellular fractions as previ-
ously described (Wysocka et al., 2001). Ten percent of these fractions
were used as input extracts and for Mnase treatment. Ninety percent
were lysed in highly denaturing guanidinium buffer for purification of
His-Ub conjugated proteins by nickel chromatography.
The list of antibodies, constructs, recombinant proteins, and oligo-
nucleotides used in this manuscript, as well as detailed procedures
for in vitro assays (ubiquitylation, acetylation, neddylation, sumoyla-
tion), FACSscan analysis, immunoprecipitation experiments, analysis
of p53 stability, ChIP experiments, and gene expression assays are
available in the Supplemental Data.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.cell.com/cgi/content/full/127/4/775/DC1/.
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